• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

After 40 investors rejected Jeff Bezos’ Amazon pitch, his parents offered $245,573 of their retirement savings

2

Current price of oil as of September 24, 2026

3

China now makes up a record 40% of all global container exports—and it’s a sign Trump’s tariffs meant to punish Chinese firms have fallen flat

1

After 40 investors rejected Jeff Bezos’ Amazon pitch, his parents offered $245,573 of their retirement savings

2

Current price of oil as of September 24, 2026

3

China now makes up a record 40% of all global container exports—and it’s a sign Trump’s tariffs meant to punish Chinese firms have fallen flat

Venture capital deals

By
Dan Primack
Dan Primack
Down Arrow Button Icon
By
Dan Primack
Dan Primack
Down Arrow Button Icon
November 30, 2011, 2:06 PM ET
Google source logo
Add Fortune on Google for similar content.

AcuFocus Inc., an Irvine, Calif.-based maker of a corneal inlay for treating near-vision loss (presbyopia), has raised $65 million in new financing. The first $40 million is equity, from Cowen Healthcare Royalty Partners, Medtronic and return backers SV Life Sciences, Versant Ventures, Carlyle Group, Accuitive Medical Ventures and Bausch & Lomb. The other $25 million is a synthetic royalty investment from Cowen. www.acufocus.com

LogiXML, a McLean, Va.-based provider of Web-based business intelligence software, has raised $10 million in growth equity funding. Summit Partners led the round, and was joined by return backer Grotech Ventures. www.logxml.com

VMTurbo, a Waltham, Mass.-based provider of workload management software in virtualized environments, has raised $10 million in Series B funding from return backers Bain Capital Ventures andHighland Capital Partners. www.vmturbo.com

Onestop Internet Inc., a Los Angeles-based provider of ecommerce services to consumer brands, has raised $9.15 million in new strategic funding from Fung Capital USA. Onestop previously raised VC funding from Bessemer Venture Partners. www.onestop.com

NuCana BioMed, a British developer of oncology therapeutics, has raised £6.74 million in Series A funding. Sofinnova Partners led the round, and was joined by Morningside Ventures, Scottish Investment Bank’s Scottish Venture Fund and Alida Capital International. www.nucanabiomed.com

Get yesterday’s VC deals

About the Author
By Dan Primack
See full bioRight Arrow Button Icon

Latest in


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.